These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12424841)

  • 1. Cell death and immune privilege.
    Ferguson TA; Green DR; Griffith TS
    Int Rev Immunol; 2002; 21(2-3):153-72. PubMed ID: 12424841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response.
    Ferguson TA; Griffith TS
    Chem Immunol Allergy; 2007; 92():140-154. PubMed ID: 17264490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vision of cell death: insights into immune privilege.
    Ferguson TA; Griffith TS
    Immunol Rev; 1997 Apr; 156():167-84. PubMed ID: 9176707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vision of cell death: Fas ligand and immune privilege 10 years later.
    Ferguson TA; Griffith TS
    Immunol Rev; 2006 Oct; 213():228-38. PubMed ID: 16972907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloantigen-driven T cell death mediated by Fas ligand and tumor necrosis factor-alpha is not essential for the induction of allograft acceptance.
    Wagener ME; Konieczny BT; Dai Z; Ring GH; Lakkis FG
    Transplantation; 2000 Jun; 69(11):2428-32. PubMed ID: 10868653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling immune privilege.
    Streilein JW
    Science; 1995 Nov; 270(5239):1158-9. PubMed ID: 7502038
    [No Abstract]   [Full Text] [Related]  

  • 9. Cell death and the immune response: a lesson from the privileged.
    Ferguson TA; Griffith TS
    J Clin Immunol; 1997 Jan; 17(1):1-10. PubMed ID: 9049780
    [No Abstract]   [Full Text] [Related]  

  • 10. See no evil, hear no evil, do no evil: the lessons of immune privilege.
    Niederkorn JY
    Nat Immunol; 2006 Apr; 7(4):354-9. PubMed ID: 16550198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine xenogeneic immune responses to the human testis: a presumed immune-privileged tissue.
    Kimmel SG; Ohbatake M; Kushida M; Merguerian P; Clarke ID; Kim PC
    Transplantation; 2000 Mar; 69(6):1075-84. PubMed ID: 10762210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
    Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
    Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments.
    Streilein JW
    Curr Opin Immunol; 1993 Jun; 5(3):428-32. PubMed ID: 8347303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
    Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune privilege, tumors, and the eye.
    Chen PW; Ksander BR
    Chem Immunol; 1999; 73():137-58. PubMed ID: 10590578
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective upregulation of fibroblast Fas ligand expression, and prolongation of Fas/Fas ligand-mediated skin allograft survival, by retinoic acid: the skin as a retinoide-inducible immune privilege site.
    Saitoh A; Kawanabe T; Weidong H; Kayagaki N; Kawamura T; Yagita H; Okumura K; Shimada S
    J Invest Dermatol; 2000 Aug; 115(2):154-61. PubMed ID: 10951230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
    Restifo NP
    Nat Med; 2000 May; 6(5):493-5. PubMed ID: 10802692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunology and immunomodulation of corneal transplantation.
    Niederkorn JY
    Int Rev Immunol; 2002; 21(2-3):173-96. PubMed ID: 12424842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.
    Griffith TS; Yu X; Herndon JM; Green DR; Ferguson TA
    Immunity; 1996 Jul; 5(1):7-16. PubMed ID: 8758890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.